TD Securities Boosts Extendicare (TSE:EXE) Price Target to C$13.00

Extendicare (TSE:EXEGet Free Report) had its price target upped by research analysts at TD Securities from C$10.50 to C$13.00 in a report released on Monday,BayStreet.CA reports. The firm currently has a “hold” rating on the stock. TD Securities’ target price suggests a potential upside of 3.50% from the stock’s previous close.

EXE has been the subject of several other reports. Cormark raised shares of Extendicare to a “moderate buy” rating in a research report on Wednesday, February 19th. Royal Bank of Canada boosted their price objective on shares of Extendicare from C$9.50 to C$11.00 and gave the company a “sector perform” rating in a research report on Thursday, November 28th. Finally, BMO Capital Markets boosted their price objective on shares of Extendicare from C$11.00 to C$13.50 in a research report on Monday. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of C$11.50.

View Our Latest Stock Analysis on EXE

Extendicare Trading Up 1.2 %

TSE:EXE traded up C$0.15 during mid-day trading on Monday, hitting C$12.56. 213,355 shares of the stock traded hands, compared to its average volume of 172,766. The stock has a market capitalization of C$1.05 billion, a price-to-earnings ratio of 16.01 and a beta of 1.26. The company has a quick ratio of 0.98, a current ratio of 0.62 and a debt-to-equity ratio of 283.02. Extendicare has a 52 week low of C$6.63 and a 52 week high of C$12.93. The firm’s 50 day moving average is C$10.69 and its two-hundred day moving average is C$9.76.

About Extendicare

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.

Featured Stories

Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.